Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia

Jeff P. Sharman, Jan A. Burger, Jacqueline Barrientos, Philip Kuruvilla, Sima Patel, Gabriel Krigsfeld, Sowmya Srikanthan, Bothayna Messahel, Wasiulla Khan, Emma Smith, Paolo Ghia

Blood (2023) 142 (Supplement 1): 6564.

https://doi.org/10.1182/blood-2023-174751

Published: 2023

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation

Carlos A Lopez, Vernon Wu, Joanna M Rhodes, Kanti R Rai, Jacqueline Barrientos

Blood (2021) 138 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2021-153947

Published: 2021

Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon

Blood (2021) 138 (Supplement 1): 528.

https://doi.org/10.1182/blood-2021-148607

Published: 2021

Journal Articles

Clinical Outcomes of Low Histologic Grade Follicular Lymphoma with High Proliferation Index

Vernon Wu, Muhammed A Salyana, Mohammed Abdelwahed, Jacqueline Barrientos, Steven L Allen, Jonathan E Kolitz, Kristin Sticco, Joanna M Rhodes

Blood (2021) 138 (Supplement 1): 3552.

https://doi.org/10.1182/blood-2021-149525

Published: 2021

Journal Articles

Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL

Andrea Nicola Mazzarello, Mark Fitch, Anita Ng, Sabreen Bhuiya, Esha Sharma, Andrew Shih, Martina Cardillo, Steven L Allen, Jonathan E Kolitz, Jacqueline Barrientos, Kanti R Rai, Marc Hellerstein, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 2622.

https://doi.org/10.1182/blood-2021-154224

Published: 2021

Journal Articles

Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL

Florencia Palacios, Gonzalo Blanco, Kamala Vanarsa, Poojitha Dugyala, Steven L Allen, Yasmine Kieso, Anna Puiggros, Jacqueline Barrientos, Xavier Calvo, Jonathan E Kolitz, Eva Gimeno, Joanna M Rhodes, ANA Ferrer, Kanti R Rai, Blanca Espinet, Chandra Mohan, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 2625.

https://doi.org/10.1182/blood-2021-152514

Published: 2021

Journal Articles

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Bryone J. Kuss, Stephen Opat, Ian W. Flinn, Xavier C. Badoux, Alessandra Tedeschi, Eva Gonzalez-Barca, John M. Pagel, Ryan Jacobs, Jacqueline Barrientos, Edith Szafer-Glusman, Cathy Zhou, Joi Ninomoto, James P. Dean, Constantine S. Tam, William G. Wierda

Blood (2021) 138 (Supplement 1): 68.

https://doi.org/10.1182/blood-2021-144544

Published: 2021

Journal Articles

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Hun Ju Lee, Michael Choi, Tanya Siddiqi, Jacqueline Barrientos, William G. Wierda, Iris Isufi, Joseph Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori A. Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Yao Wang, Michael Wang, Catriona Jamieson, Thomas J. Kipps

Blood (2021) 138 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2021-148779

Published: 2021

Journal Articles

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

Shih-Shih Chen, Jacqueline Barrientos, Xiao-Jie Yan, Uwe Wirtz, Edith Szafer-Glusman, Kanti R Rai, Nicholas Chiorazzi

Blood (2021) 138 (Supplement 1): 3708.

https://doi.org/10.1182/blood-2021-153685

Published: 2021

Journal Articles

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Blood (2021) 138 (Supplement 1): 1562.

https://doi.org/10.1182/blood-2021-150462

Published: 2021

Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Blood (2020) 135 (15): 1204–1213.

https://doi.org/10.1182/blood.2018884940

Published: 2020

Includes: Supplemental data

Journal Articles

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Blood (2017) 129 (5): 553–560.

https://doi.org/10.1182/blood-2016-01-689422

Published: 2017

Journal Articles

IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions

Piers E. M. Patten, Charles C. Chu, Emilia Albesiano, Rajendra N. Damle, Xiao-Jie Yan, Dorothy Kim, Lu Zhang, Amanda R. Magli, Jacqueline Barrientos, Jonathan E. Kolitz, Steven L. Allen, Kanti R. Rai, Sergio Roa, Patricia K. Mongini, Thomas MacCarthy, Matthew D. Scharff, Nicholas Chiorazzi

Blood (2012) 120 (24): 4802–4811.

https://doi.org/10.1182/blood-2012-08-449744

Published: 2012

Includes: Supplemental data

Journal Articles

Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy

Rebecca Elstrom, MD, Peter Martin, Katya Ostrow, Jacqueline Barrientos, Richard R. Furman, Jia Ruan, Michael Schuster, Tsiporah Shore, Amy Chadburn, Morton Coleman, MD, John P. Leonard, MD

Blood (2008) 112 (11): 4940.

https://doi.org/10.1182/blood.V112.11.4940.4940

Published: 2008

Journal Articles

Bcl2 Associated Induction of the Suppressor of Cytokine Signaling-3 (SOCS3) Gene Involves Activation of the p44/42 MAPK Pathway.

Julie Kim, MD, PhD, Sofya Rodov, Jacqueline Barrientos, MD, Ravitharan Krishnadasan, MD, K. Gary J. Vanasse, MD

Blood (2005) 106 (11): 2286.

https://doi.org/10.1182/blood.V106.11.2286.2286

Published: 2005

NARROW

Tailor: Interventional Study Evaluating Physician's Choice of Ibrutinib Monotherapy or Ibrutinib-Venetoclax Combination Using Dose Modifications and Alternate Dosing Approaches in Patients with Untreated Chronic Lymphocytic Leukemia

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Ibrutinib Combined with Obinutuzumab and CHOP (I-OCHOP) for Richter Transformation

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Clinical Outcomes of Low Histologic Grade Follicular Lymphoma with High Proliferation Index

Analyses of the Kinetics and Phenotype of Multiple Intraclonal CXCR4/CD5 B Cell Subsets Suggest Differences in Life Cycle Transitioning in CLL

Serum Proteomic Analyses Suggest That the HMGB1 and Other Inflammatory Pathways Are Operational in MBL and Are Less in Overt CLL

First-Line Treatment with Ibrutinib (Ibr) Plus Venetoclax (Ven) for Chronic Lymphocytic Leukemia (CLL): 2-Year Post-Randomization Disease-Free Survival (DFS) Results from the Minimal Residual Disease (MRD) Cohort of the Phase 2 Captivate Study

Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Efficacy of Ibrutinib Monotherapy in Pre-Clinical Mouse Models of Richter Transformation: Ibrutinib Effectively Reduces the Incidence of Richter Transformation but Fails in Treating Transformed Lymphoma, Especially in Primary Lymphoid Tissue

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions

Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy

Bcl2 Associated Induction of the Suppressor of Cytokine Signaling-3 (SOCS3) Gene Involves Activation of the p44/42 MAPK Pathway.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only